<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67145">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01916239</url>
  </required_header>
  <id_info>
    <org_study_id>CEBAS-CSIC-2</org_study_id>
    <nct_id>NCT01916239</nct_id>
  </id_info>
  <brief_title>Pomegranate Extract Supplementation in Colorectal Cancer Patients</brief_title>
  <acronym>POMEcolon</acronym>
  <official_title>Phase I-II Study of Pomegranate Extract Formulations in Colorectal Cancer Patients: Metabolic and Gene Expression Profiling in Tumoral and Normal Colon Tissues</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Council, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario Reina Sofia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Research Council, Spain</source>
  <oversight_info>
    <authority>Spain: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The most relevant pomegranate phenolics (ellagitannins and ellagic acid) are extensively
      metabolized by the human gut microbiota to yield a number of metabolites called urolithins
      (mainly Uro-A). Urolithins have been reported to regulate in vivo the expression of genes
      involved in inflammation and cancer. Our hypothesis is that urolithins can be detected in
      the human colon mucosa where these metabolites can exert anti-inflammatory and anti-cancer
      activities. After colonoscopy and diagnosis, colorectal cancer patients will consume
      capsules containing three different pomegranate extract formulations until surgery. The aims
      of this trial are:

        -  To evaluate the disposition of pomegranate phenolics and urolithins in tumoral and
           normal colon tissues.

        -  To evaluate gene expression profiling and protein markers in tumoral and normal colon
           tissues from these patients.

        -  To compare different pomegranate extract formulations on the above.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Phenolics and derived metabolites in colon tissues, plasma and urine.</measure>
    <time_frame>Change from baseline at 15 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Occurrence of phenolics and gut-microbiota derived metabolites in tumoral and colon tissues, urine and plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene expression profiling in colon tissues</measure>
    <time_frame>Change from baseline at 15 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gene expression profile changes in tumoral and normal colon tissues</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IGF-1 (insulin-like growth factor-1)</measure>
    <time_frame>Change from baseline at 15 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in circulating IGF-1 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CEA (carcnoembryonic antigen)</measure>
    <time_frame>Change from baseline at 15 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in circulating CEA levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Change from baseline at 15 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change in markers involved in hepatic and renal functions: GGT, AST, ALP, ALT, CPK, urate, creatinin, albumin, bilirubin, LDH.
Change in hematological variables: leucocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, hemoglobin, hematocrit, mean corpuscular volume, mean platelet volume, platelets, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration.
Intolerance, dyspepsia, allergic reactions, constipation, diarrhea, abdominal pain, nausea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microRNA expression profiling in colon tissues</measure>
    <time_frame>Change from baseline at 15 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>microRNA (miR) expression profile change in tumoral and normal colon tissues</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Standard pomegranate extract formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard pomegranate extract formulation containing 20% punicalagin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pomegranate extract formulation-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New pomegranate extract formulation-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pomegranate extract formulation-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New pomegranate extract formulation-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Standard pomegranate extract formulation</intervention_name>
    <description>Standard pomegranate extract formulation containing 20% punicalagin</description>
    <arm_group_label>Standard pomegranate extract formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pomegranate extract formulation-1</intervention_name>
    <description>New pomegranate extract formulation-1</description>
    <arm_group_label>Pomegranate extract formulation-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pomegranate extract formulation-2</intervention_name>
    <description>New pomegranate extract formulation-2</description>
    <arm_group_label>Pomegranate extract formulation-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Colorectal cancer diagnosis.

          -  Surgery required.

          -  WHO status: between 0 and 2.

          -  Hemoglobin &gt;10 g/dL

          -  ALT &gt;2.5-fold above the normal value.

          -  Serum Bilirubin &gt;1.5-fold above the normal value.

          -  Creatinine &lt;140 micromol/L

        Exclusion Criteria:

          -  Patients who do not satisfy inclusion criteria and,

          -  Active pectic ulcer.

          -  Pregnancy or breastfeeding.

          -  Alcoholism.

          -  Chemotherapy or radiotherapy a month prior to recruitment.

          -  Treatment with steroids or other anti-inflammatory drugs a week prior to recruitment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Juan Carlos Espín, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Research Council (CEBAS-CSIC, Murcia, Spain)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General Universitario Reina Sofía</name>
      <address>
        <city>Murcia</city>
        <zip>30003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 7, 2013</lastchanged_date>
  <firstreceived_date>July 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Research Council, Spain</investigator_affiliation>
    <investigator_full_name>Juan Carlos Espín de Gea</investigator_full_name>
    <investigator_title>Full Research Professor</investigator_title>
  </responsible_party>
  <keyword>Pomegranate</keyword>
  <keyword>Urolithins</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Colon cancer</keyword>
  <keyword>Metabolite</keyword>
  <keyword>Gene expression</keyword>
  <keyword>microRNA</keyword>
  <keyword>Nutraceutical</keyword>
  <keyword>Food supplement</keyword>
  <keyword>Polyphenol</keyword>
  <keyword>Gut microbiota</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
